These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 31672171)

  • 1. Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.
    Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C
    J Immunother Cancer; 2019 Oct; 7(1):281. PubMed ID: 31672171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
    Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
    Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
    Santin AD; Deng W; Frumovitz M; Buza N; Bellone S; Huh W; Khleif S; Lankes HA; Ratner ES; O'Cearbhaill RE; Jazaeri AA; Birrer M
    Gynecol Oncol; 2020 Apr; 157(1):161-166. PubMed ID: 31924334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
    Hasegawa T; Ozaki Y; Inoue T; Watanabe Y; Fukuhara M; Yamaura T; Muto S; Okabe N; Higuchi M; Shio Y; Suzuki H
    J Med Case Rep; 2019 Oct; 13(1):316. PubMed ID: 31647029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report.
    Guidi A; Violati M; Blasi M; Ferrari E; Luciani A; Codecà C; Ferrari D
    Tumori; 2020 Dec; 106(6):NP23-NP28. PubMed ID: 32851941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
    de Jong C; Peters BJM; Schramel FMNH
    Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report.
    Kono K; Nakashima K; Tsubata Y; Amano Y; Kawakado K; Yanagawa T; Isobe T
    Thorac Cancer; 2024 Aug; 15(22):1714-1717. PubMed ID: 38956899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
    Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
    Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Minion LE; Tewari KS
    Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
    Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
    Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.
    Zhang PF; Xie D; Li Q
    Future Oncol; 2020 Jun; 16(17):1189-1198. PubMed ID: 32407173
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V; Grän F; Weber J; Gesierich A; Goebeler M; Schilling B
    J Immunother Cancer; 2019 Jul; 7(1):181. PubMed ID: 31300044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
    Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
    Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
    Mouri A; Kaira K; Yamaguchi O; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):873-880. PubMed ID: 31444618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
    Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
    J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.